Tioma Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tioma Therapeutics, Inc. - overview
Location
St. Louis, MO, US
Primary Industry
Pharmaceuticals
About
Based in the US, Tioma Therapeutics, formerly known as Vasculox, focuses on immuno-oncology and developing anti-CD47 antibodies to treat solid and hematologic cancers. The company was founded by William Frazier, a professor of Biochemistry, Molecular Biophysics, Cell Biology, and Biomedical Engineering at Washington University School of Medicine. John Donovan is the president and CEO of the company. In August 2016, new investors Novo Ventures, RiverVest Ventures, Roche Venture Fund and SR One co-led USD 86 million in a Series A funding round for Tioma Therapeutics, Inc.
Current Investors
RiverVest Ventures Partners, SR One, Novo Holdings
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development, Biomaterials
Website
www.tiomatherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Tioma Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.